目的 为完善药品抽检结果信息公开提供参考。方法 通过文献资料和信息公开措施研究,结合案例对我国药品抽检结果信息公开的历史沿革、公开形式、公开现状及意义等进行分析,提出完善建议。结果与结论 抽检结果信息公开有助于提升政府公信力、保障公众知情权、震慑不法企业和助推药品质量提升,建议药监部门借鉴美国食品药品监督管理局(FDA)经验提高信息公开的法律地位,加强时效性、成果转化、舆情监测,并在企业信用修复后将企业信息从公开环境中移除,同时建议社会各界正确认识并理性对待抽检信息公开内容,以完善药品抽检结果信息公开,促进药品质量安全的社会共建共治。
Abstract
OBJECTIVE To provide a reference to improve the information disclosure of drug sampling and testing. METHODS Through literature and information disclosure measures research, combined with examples, the historical evolution, disclosure form, disclosure status, and significance of the drug sampling and testing results disclosure in China was analyzed, suggestions was made. RESULTS AND CONCLUSION The disclosure of drug sampling and testing results are helpful to improve the government′s credibility, protect the public′s right to know, deter illegal enterprises and promote the improvement of drug quality. It is suggested that the drug regulatory department learn from the FDA′s experience to improve the legal status of information disclosure, strengthen timeliness, transform results, monitor public opinion and remove the enterprise information from public environment after credit repair,and all circles of society correctly understand and rationally treat the information disclosure content, in order to improve the information disclosure of drug sampling and testing and promote the social co-construction and co-governance of drug quality and safety.
关键词
药品抽检 /
信息公开 /
现状
{{custom_keyword}} /
Key words
drug sampling and testing /
information disclosure /
current status
{{custom_keyword}} /
中图分类号：
R95
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] YUAN Q Z K. The spread of food and drug public opinion and public opinion guidance[J].Econ Her (经济导刊), 2018, 6: 64-67.
[2] ZHENG J T, LI L. Comparing network public opinion about the Changchun Changsheng vaccine event and Shandong vaccine event [J]. Chin J Public Manage(中国公共卫生管理), 2019, 35 (3): 321-324.
[3] YAN J Y. People-centered news release on food and drug safety [J]. Chin Food Drug Adm(中国食品药品监管), 2016 (11): 16-17.
[4] ZHANG X. The amended "Regulations of the People′s Republic of China on the Disclosure of Government Information" made it clear that publicity is the norm,and non-publicity is the exception [N]. Economoc Daily, 2019-04-17(4).
[5] GAO X J. Analysis of the evolution of the drug sampling and testing mechanism and analysis of drug sampling and testing conditions [C]. Proceedings of the 7th Provincial Member Congress and Academic Annual Meeting of Sichuan Pharmaceutical Association, 2011: 51-56.
[6] ZHU J, JIANG H, HU Z Y. Third Discussion on Building a "National Defense System" for Post-market Drug Supervision[N]. China Pharmaceutical News, 2019-06-25 (3).
[7] State Food and Drug Administration. Measures of the State Food and Drug Administration for Disclosure of Government Information [EB/OL]. (2017-12-22) [2019-07-06]. http://www.nmpa.gov.cn/WS04/CL2199/325607.html.
[8] China Food and Drug Administration. CFDA Notice of the Measures for the Disclosure of Food and Drug Safety Supervision Information (Food and Drug Administration Law [2017] No.125) [EB/OL]. (2017-12-22) [2019-07-06]. http://www.nmpa.gov.cn/WS04/CL2199/325607.html.
[9] National Medical Products Administration. Government information base contents for active disclosure of National Medical Products Administration[EB/OL].(2019-06-26) [2019-12-06]. http://www.nmpa.gov.cn/WS04/CL2078/338551.html.
[10] WANG C, CHENG S H. Analysis and suggestion on effect of drug safety regulatory during national drug sampling and testing[J]. Chin Pharm J (中国药学杂志),2016,51(20): 1815-1818.
[11] HUANG B B,XU M Z,YANG Q Y, et al. Review of the approved supplementary testing methods and items on identifying adulterated chemical substances in traditional Chinese medicine preparations and herbal medicines[J]. Chin J Pharm Anal(药物分析杂志), 2014, 34 (9): 1701-1708.
[12] Review of the approved supplementary testing methods and items on identifying adulterated chemical substances in traditional Chinese medicine preparations and herbal medicines[J]. Chin Health Ind(中国卫生产业), 2018, 27:151-153.
[13] China Food and Drug Administration.Actively carrying out exploratory research and guiding enterprises to improve drug quality [EB/OL].(2017-06-23) [2019-07-06]. http://www.nmpa.gov.cn/WS04/CL2168/329400.html.
[14] WANG J C, HE J Q, HU Z Y. Second Discussion on Building a "National Defense System" for Post-market Drug Supervision [N]. China Pharmaceutical News, 2019-05-27 (3).
[15] National Institutes for Food and Drug Control. Exploratory Research of National Drug Sampling and testing (1) [EB/OL]. (2017-06-21) [2019-07-07]. https://www.nifdc.org.cn/nifdc/fwzn/ypchytsxyj/9553.html.
[16] National Institutes for Food and Drug Control. Exploratory Research of National Drug Sampling and testing (2) [EB/OL].(2018-01-29) [2019-07-07]https://www.nifdc.org.cn/nifdc/fwzn/ypchytsxyj/10525.html.
[17] National Institutes for Food and Drug Control. Exploratory Research of National Drug Sampling and testing (3) [EB/OL].(2018-04-26) [2019-07-07].https://www.nifdc.org.cn/nifdc/fwzn/ypchytsxyj/10978.html.
[18] National Institutes for Food and Drug Control. Exploratory Research of National Drug Sampling and testing (4) [EB/OL].(2018-12-12) [2019-07-07].https://www.nifdc.org.cn/nifdc/fwzn/ypchytsxyj/11842.html.
[19] National Institutes for Food and Drug Control. Exploratory Research of National Drug Sampling and testing (5) [EB/OL]. (2019-05-17) [2019-07-07]. https://www.nifdc.org.cn/nifdc/fwzn/ypchytsxyj/20190517091800.html.
[20] National Institutes for Food and Drug Control.National Drug Sampling and testing Annual Report (2016)[EB/OL],(2017-10-09) [2019-07-08].http://www.nifdc.org.cn/nifdc/fwzn/ypchytsxyj/9872.html.
[21] National Institutes for Food and Drug Control.National Drug Sampling and testing Annual Report(2017)[EB/OL].(2018-06-05) [2019-07-08]. http://www.nifdc.org.cn/nifdc/fwzn/ypchytsxyj/11119. html.
[22] National Institutes for Food and Drug Control.National Drug Sampling and testing Annual Report(2018)[EB/OL].(2018-08-07) [2019-08-15]. https://www.nifdc.org.cn/nifdc/fwzn/ypchytsxyj/ 20190807101035.html.
[23] National Medical Products Administration. NMPA: fully guarding the quality and safety of drugs and medical devices used for epidemic prevention[EB/OL].(2020-03-13) [2020-03-20]. http://www.nmpa.gov.cn/WS04/CL2056/375759.html.
[24] YI Y H, WANG G P, GAO H J. Brief introduction on big data practice of FDA and its enlightenment to China[J]. Shanghai Med Pharm J(上海医药), 2017, 38 (9): 60-65.
[25] CHEN Y F, WANG S. Standard, scope and strategy of the information disclosure on major food and drug safety events[J]. Chin Pharm Aff(中国药事), 2012, 26 (2): 129-133.
[26] CHEN Y F,ZHAO M. Studying on information disclosure of drug administrative supervision[J]. Chin Health Serv Manage(中国卫生事业管理), 2011,31(6):426-429.
[27] CHEN J Y,YANG Y. Research of disclosure and confidentiality of FDA information in US [J]. Chin Pharm J(中国药学杂志), 2019, 54 (1): 66-71.
[28] LIAO S W,CHEN Y F,SHAO R. Comparative analysis between SFDA and FDA of drug administration information disclosure system[J]. Chin Lic Pharm(中国执业药师), 2010, 7 (5): 38-41.
[29] DAN L H. Current Situation,Problems and Countermeasures of Drug Safety Information Disclosure in China [D]. Kunming: Yunnan University, 2012.
[30] LIANG H Y. Attention indicators of public opinion incidents caused by drug safety issues[J]. News Diss(新闻传播), 2019 (9): 51-52.
[31] Centre for Food Safety of Government of the Hong Kong Special Administrative Region. Results of Sample with Irregularity[EB/OL].(2020-03-27) [2020-03-29]. https://www.cfs.gov.hk/english/unsat_samples/unsat_samples.html.
[32] Office of the State Council. Guiding Opinions of the General Office of the State Council on Accelerating the Construction of the Social Credit System and Building a New Credit-based Supervision Mechanism[EB/OL]. (209-07-16) [2020-03-07]. http://www.gov.cn/zhengce/content/2019-07/16/content_5410120.html.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(4690 KB)
